Emily Silverman, MD
Endocrinology, Diabetes & Metabolism · Bayonne, NJNPI 1346695467
Payments from drug & device makers
Across 419 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Dexcom, Inc.$989
- Novo Nordisk$755
- AstraZeneca$419
- Insulet Corporation$375
- Medtronic$372
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,962100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 137 | $1,315 |
| Dexcom, Inc. | 25 | $989 |
| Novo Nordisk | 50 | $755 |
| AstraZeneca | 22 | $419 |
| Insulet Corporation | 12 | $375 |
| Medtronic | 12 | $372 |
| Corcept Therapeutics | 20 | $372 |
| Xeris Pharmaceuticals, Inc. | 24 | $353 |
| Amgen(2 entities) | 22 | $349 |
| Bayer | 9 | $271 |
| Sanofi-aventis U.S. LLC | 15 | $228 |
| Tandem Diabetes Care, Inc. | 13 | $208 |
| Abbott | 9 | $137 |
| Recordati_rare_diseases_inc. | 6 | $100 |
| Boehringer Ingelheim | 5 | $86 |
| Cequr Corporation | 2 | $75 |
| IBSA Pharma Inc. | 4 | $60 |
| Ascendis Pharma Endocrinology Inc | 3 | $55 |
| Mannkind Corporation | 4 | $53 |
| Madrigal Pharmaceuticals | 2 | $40 |
| Currax Pharmaceuticals LLC | 2 | $34 |
| Amphastar Pharmaceuticals, Inc. | 2 | $31 |
| Merck | 2 | $31 |
| Embecta Corp. | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $26 |
| GSK | 2 | $25 |
| Alkermes, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
| Nevro Corp. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| AbbVie | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Vistapharm, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$364
- DEXCOM G7 GSS (161)$260
- Omnipod$150
- FARXIGA$128
- Kerendia$127
- MOUNJARO$108
How this compares
$6,974 in reported general payments places this provider in the 75th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $244,304 |
| JardianceEmpagliflozin | 196 | $199,369 |
| MounjaroTirzepatide | 108 | $178,918 |
| TrulicityDulaglutide | 104 | $158,965 |
| FarxigaDapagliflozin Propanediol | 105 | $98,019 |
| RybelsusSemaglutide | 34 | $59,347 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $24,409 |
| Humalog Kwikpen U-100Insulin Lispro | 87 | $22,902 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $19,367 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $17,777 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 17 | $16,998 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $16,518 |
| JanuviaSitagliptin Phosphate | 12 | $16,412 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 42 | $14,843 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 54 | $14,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,315 | $337,883212 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $755 | $305,591223 claims |
| Boehringer IngelheimJardiance | $86 | $199,369196 claims |
| AstraZenecaFarxiga | $419 | $98,019105 claims |
| MerckJanumet, Januvia | $31 | $34,18928 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $2,120212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Bayonne
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Sunil AsnaniBrick$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.